ClearPoint Neuro, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies (Tables)

Basis of Presentation and Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2018

Schedule of the level of the inputs used in the company's fair value calculation for instruments carried at fair value

The table below reflects the level of the inputs used in the Company’s fair value calculations:

	Quoted Prices in Active Markets (Level 1)		Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value

March 31, 2018
Derivative liabilities - warrants	$	-	$	-	$	15,875	$	15,875
Derivative liabilities – debt conversion feature	$	-	$	-	$	14,000	$	14,000
December 31, 2017
Derivative liabilities - warrants	$	-	$	-	$	79,286	$	79,286
Derivative liabilities – debt conversion feature	$	-	$	-	$	16,500	$	16,500

Schedule of the carrying values and the estimated fair values, based on level 3 inputs

The table below reflects the carrying values and the estimated fair values, based on Level 3 inputs, of the Company’s outstanding notes payable, including the related accrued interest, at March 31, 2018 and December 31, 2017:

	Carrying Values		Estimated Fair Values
March 31, 2018
Senior secured note payable, including accrued interest	$	2,027,500		$	2,027,500
2014 junior secured notes payable, including accrued interest	$	1,903,031		$	1,983,375
2010 junior secured notes payable, including accrued interest	$	1,938,635		$	3,778,750

December 31, 2017
Senior secured note payable, including accrued interest	$	2,028,111		$	2,028,111
2014 junior secured notes payable, including accrued interest	$	1,942,195		$	2,042,625
2010 junior secured notes payable, including accrued interest	$	1,796,042		$	3,752,500

Schedule of revenue by source

Information with respect to revenue by source is as follows:

	Three Months Ended March 31,
	2018		2017
Disposable products:
Functional neurology	$	1,148,870	$	1,290,484
Biologics and drug delivery		210,930		372,965
Total disposable product revenue		1,359,800		1,663,449
Capital equipment		178,798		258,766
Total product revenue		1,538,598		1,922,215
Rental, service and other		84,768		84,857
Total revenue	$	1,623,366	$	2,007,072

Schedule of concentration of risk

Information with respect to customers that accounted for sales in excess of 10% of total sales in the three-month periods ended March 31, 2018 and 2017 is as follows:

	Three Months Ended March 31,
	2018	2017
Customer - 1	13%	12%

Information with respect to accounts receivable from those customers who comprised more than 10% of accounts receivable at March 31, 2018 and December 31, 2017 is as follows:

	March 31, 2018		December 31, 2017
Customer – 1	20%		10%